2-溴-5-氯-3-羟基吡啶 | 127561-70-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-5-氯-3-羟基吡啶
• 英文名称: 2-bromo-5-chloropyridin-3-ol
• CAS: 127561-70-0
• 化学式: C₅H₃BrClNO
• mdl: MFCD09835245
• 分子量: 208.442
• InChiKey: CXEWQBDKAZUKBB-UHFFFAOYSA-N

物化性质

• 沸点：
  326.1±37.0 °C(Predicted)
• 密度：
  1.908±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-溴-5-氯-3-羟基吡啶 在 copper(l) iodide 、 trans-bis(triphenylphosphine)palladium dichloride 、 sodium hexamethyldisilazane 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  Syk 억제제

  摘要：

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.

  公开号：

  KR20160037198A
• 作为产物：
  描述：

  5-氯-3-羟基吡啶 在 溴 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 2-溴-5-氯-3-羟基吡啶
  参考文献：
  名称：

  Syk 억제제

  摘要：

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.

  公开号：

  KR20160037198A

文献信息

• [EN] PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE PYRIMIDINE TBK/IKKε ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019079373A1

  公开（公告）日：2019-04-25

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  这项发明涉及公式I的化合物及其药用可接受的组合物，可用作TBK/IKKε抑制剂。
• [EN] COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON
  申请人：PTC THERAPEUTICS INC

  公开号：WO2020231977A1

  公开（公告）日：2020-11-19

  The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

  本描述涉及化合物、形式、以及这些化合物的药物组合物和使用这些化合物、形式或组合物治疗或改善亨廷顿病的方法。具体而言，本描述涉及公式(I)、公式(II)或公式(III)的取代单环杂环烷基化合物，以及这些化合物的形式和药物组合物，以及使用这些化合物、形式或组合物治疗或改善亨廷顿病的方法。
• [EN] COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET COMPOSITIONS PERMETTANT D'INHIBER L'ACTIVITÉ DE HIF2-ALPHA ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2021220170A1

  公开（公告）日：2021-11-04

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease. The compounds are inhibitors or modulators of HIF2alpha.

  本发明涉及公式（I）的化合物或其药用可接受的盐形式，其中取代基如规范中所定义；制备该化合物的中间体；包含该化合物的药物组合物；以及利用该化合物治疗疾病。这些化合物是HIF2alpha的抑制剂或调节剂。
• 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
  申请人：Bristol-Myers Squibb Company

  公开号：US04954502A1

  公开（公告）日：1990-09-04

  A series of 1,4-disubstituted piperazine derivatives comprised of indol-3-ylalkyl and substituted pyridin-2-yl substituent groups. These compounds are useful as antidepressant agents.

  一系列包含吲哚-3-基烷基和取代吡啶-2-基取代基团的1,4-二取代哌嗪衍生物。这些化合物可用作抗抑郁剂。
• CHROMAN DERIVATIVES AS TRPM8 INHIBITORS
  申请人：AMGEN INC.

  公开号：US20140045855A1

  公开（公告）日：2014-02-13

  Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  Formula I的Chroman化合物和衍生物是TRPM8的有用抑制剂。这些化合物在治疗多种由TRPM8介导的疾病和症状方面具有用途，并可用于制备治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括，但不限于，偏头痛和神经病性疼痛。Formula I的化合物具有以下结构：变量的定义在此提供。